451 related articles for article (PubMed ID: 32199889)
1. Should biologics for psoriasis be interrupted in the era of COVID-19?
Lebwohl M; Rivera-Oyola R; Murrell DF
J Am Acad Dermatol; 2020 May; 82(5):1217-1218. PubMed ID: 32199889
[No Abstract] [Full Text] [Related]
2. Should patients stop their biologic treatment during the COVID-19 pandemic.
Bashyam AM; Feldman SR
J Dermatolog Treat; 2020 Jun; 31(4):317-318. PubMed ID: 32191143
[No Abstract] [Full Text] [Related]
3. Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.
Nassim D; Jfri A; Litvinov IV; Netchiporouk E
J Cutan Med Surg; 2020; 24(4):420-421. PubMed ID: 32449619
[No Abstract] [Full Text] [Related]
4. Asthma, biologics, corticosteroids, and coronavirus disease 2019.
Akenroye AT; Wood R; Keet C
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):12-13. PubMed ID: 32387535
[No Abstract] [Full Text] [Related]
5. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
Conti A; Lasagni C; Bigi L; Pellacani G
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e360-e361. PubMed ID: 32379913
[No Abstract] [Full Text] [Related]
6. Guttate psoriasis secondary to COVID-19.
Gananandan K; Sacks B; Ewing I
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32784237
[No Abstract] [Full Text] [Related]
7. The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Syed MN; Shin DB; Wan MT; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Nov; 83(5):1523-1526. PubMed ID: 32622891
[No Abstract] [Full Text] [Related]
8. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Mugheddu C; Pizzatti L; Sanna S; Atzori L; Rongioletti F
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e376-e378. PubMed ID: 32385859
[No Abstract] [Full Text] [Related]
9. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
Haberman R; Axelrad J; Chen A; Castillo R; Yan D; Izmirly P; Neimann A; Adhikari S; Hudesman D; Scher JU
N Engl J Med; 2020 Jul; 383(1):85-88. PubMed ID: 32348641
[No Abstract] [Full Text] [Related]
10. Psoriasis-COVID 19 Infection: Treatment Options.
Tampouratzi E; Kanni T; Katsantonis J; Douvali T
Skinmed; 2020; 18(2):81-82. PubMed ID: 32501789
[No Abstract] [Full Text] [Related]
11. Biologics for psoriasis in COVID-19 era: What do we know?
Megna M; Napolitano M; Patruno C; Fabbrocini G
Dermatol Ther; 2020 Jul; 33(4):e13467. PubMed ID: 32338424
[No Abstract] [Full Text] [Related]
12. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M; Tofani L; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2020 Aug; 20(8):829-830. PubMed ID: 32510244
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.
Balestri R; Rech G; Girardelli CR
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e357-e358. PubMed ID: 32358791
[No Abstract] [Full Text] [Related]
14. Reply: "Biologics for psoriasis during COVID-19 outbreak".
Di Lernia V
J Am Acad Dermatol; 2020 Jun; 82(6):e217-e218. PubMed ID: 32283234
[No Abstract] [Full Text] [Related]
15. The management of biologics in dermatologic patients in the 2019-nCoV era.
Plachouri KM; Georgiou S
J Dermatolog Treat; 2020 Jun; 31(4):319. PubMed ID: 32281897
[No Abstract] [Full Text] [Related]
16. Are Patients With Alcohol Use Disorders at Increased Risk for Covid-19 Infection?
Testino G
Alcohol Alcohol; 2020 Jun; 55(4):344-346. PubMed ID: 32400858
[No Abstract] [Full Text] [Related]
17. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients.
Lin D; Liu L; Zhang M; Hu Y; Yang Q; Guo J; Guo Y; Dai Y; Xu Y; Cai Y; Chen X; Zhang Z; Huang K
Sci China Life Sci; 2020 Apr; 63(4):606-609. PubMed ID: 32170625
[No Abstract] [Full Text] [Related]
18. Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.
Benhadou F; Del Marmol V
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e363-e364. PubMed ID: 32379925
[No Abstract] [Full Text] [Related]
19. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases.
Yang C; Jin Z
JAMA Cardiol; 2020 Jul; 5(7):743-744. PubMed ID: 32211809
[No Abstract] [Full Text] [Related]
20. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Yim RM; Singh I; Armstrong AW
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
